Roche recorded growth thanks to new products

To the good performance was mainly driven by recently launched products. You have loss of sales from generics, more than compensated for.

said As Roche on Wednesday, sales for the first three months of 2019 to 14.8 billion francs, an increase of 9 percent. Fraud constant exchange rates (CER) increase of 8 percent. Roche shall, traditionally for the first and third quarter sales figures.

pharmaceuticals division strong

The pharmaceuticals division in the first three months of 11.9 billion Swiss francs (12%/ 10% CC) for the lion's share contributed to revenue. In the area of Diagnostics revenues in the amount of 2.9 billion (unchanged/ 1% CER) to beech.

The submitted sales figures so predominantly on the estimates of the AWP analysts surveyed. Only the Diagnostics division has failed to meet the expectations of an average of 3.0 billion Swiss francs, slightly.

Swan-satisfied

"We started with a strong sales growth in the year, especially in the case of the newly introduced drugs of our pharmaceuticals Division," CEO Severin Schwan is quoted in the message. The demand for these new products remain high.

Roche owes its good performance but only newly introduced agents such as Immune-therapeutic agent Tecentriq or the MS-medium Ocrevus. According to the CEO of the Swan, the MS medium is the most successful product launch in the history of Roche. There is also the older Blockbuster Herceptin, Avastin and Mabthera, all of which have performed better than analysts expected. Thus, the negative influence of generic products failed in the case of these three funds is weaker than feared.

For the further course of the Year, Roche has raised its targets. The Management at constant exchange rates sales growth in the middle single-digit percent range in view. So far, Roche had spent here a range of a low to medium growth.

(step/sda)

Created: 17.04.2019, 07:56 PM